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Abstract
Background: Tuberculosis co-infected with human immunodeficiency virus constitutes a large
proportion of patients in Ethiopia. Isoniazid preventive therapy is recommended for treatment of latent
Tuberculosis infection. Non-adherence is the major problem to control tuberculosis. However the
prevalence of adherence and associated factors has not be studied in those HIV positive patients who
were on Isoniazid preventive therapy in   public health facilities of Addis Ababa.
Objective: The objective of this study was to assess the prevalence of adherence to Isoniazid
preventive therapy and associated factors among People living with HIV in Addis Ababa.
Methods: Health facility based cross sectional study was conducted in Addis Ababa. 10 health centers
and 2 hospitals were selected randomly from a sampling frame consisted of 24 health centers and 5
hospitals, patients were consecutively recruited till the required sample size was obtained on their exit
to home from Dec 2010 to February 2011. A total of 381 HIV positive patients who were on Isoniazid
preventive therapy were interviewed by trained data collectors. Data were double entered, cleaned, and
analyzed using Epi Info version 3.5 and SPSS version 16.
Result: The prevalence of adherence to Isoniazid preventive therapy was found to be 89.5%.Those
patients who had taken Isoniazid for >=5 months were more likely to be adherents than those who took
1-2 monhts AOR [(95%CI)= 5.091(1.412-18.359)]. Decision that were made by friends for the patients
to start Isoniazid preventive therapy were less likely to be adherent than decision made by the patients
them selves AOR [(95%CI)=0.096(0.011-0.815)]. Among the reasons mentioned by non-adherents for
missing doses were forgetting, out of stock of Isoniazid in the health facilities and side effects.
Conclusion and Recommendation: The prevalence of adherence to Isoniazid preventive therapy in
HIV positive patients was higher than what was reported in Diredawa 84.86% and other Africa
countries. Counseling those patients who are at the beginning of therapy is recommended. Adressing
the reason for non-adherence through strong Information Education Communication is also important
to enhance adherence so as to control Tuberculosis.
11 Introduction
Globally the number of people living with HIV continues to grow, as does the number of deaths
from HIV/AIDS. According to UNAIDS report, 33.3 million people were living with HIV in
2009. There were 1.8 million deaths because of HIV in the year 2009. Sub Saharan Africa
continues to bear the burden of the global epidemic. A total of 22.5 million (67.7%) of the global
people were living with HIV in 2009 in the sub-Saharan Africa and an adult prevalence of 5% is
reported (1-3).
With an estimated 1.1 million people living with HIV, Ethiopia has one of the largest
populations of HIV infected people in the world. However, HIV prevalence among the adult
population is lower than many sub-Saharan African countries. The national and Addis Ababa
adult HIV prevalence in 2010 was  estimated to be 2.4% and 9.2% respectively (4, 5).
TB although curable, is one of the most common causes of HIV-related illness and death. 11.5
million adults living with HIV/AIDS are estimated to be co-infected with Mycobacterium
tuberculosis, with 71% of those co-infected living in sub-Saharan Africa. In Ethiopia routine data
from 44 sites in the year 2005/2006 showed 41% of TB patients are HIV positive.Another
routine data collected in 2006/2007 that co-infection is 31% (2, 6).
HIV is the most important factor fuelling the TB epidemic in populations with a high HIV
prevalence.Tuberculosis is the most frequent life-threatening opportunistic disease among people
living with HIV and remains a leading cause of mortality (7). Treatement for latent TB
infection(LTBI) is  an important strategy if tuberculosis is to be eradicated by 2050,Usually
consists of 6 to 12 months of isoniazid(INH).Isoniazid preventive therapy (IPT) has a significant
protective effect on those HIV postive clients with out active TB by preventing the development
of TB disease (8, 9).
2A significant barrier to effective medical treatment is the patient’s failure to follow the
recommendations of his or her physician or other healthcare provider. Patient non- adherence
sometimes called non-compliance can take many forms; the advice given to patients by their
healthcare professionals to cure or control disease is too often misunderstood, carried out
incorrectly, forgotten, or even completely ignored. Non- adherence carries a huge economic
burden. Yearly expenditures for the consequences of non-a adherence have been estimated to be
in the hundreds of billions of US dollars.In addition to the most obvious direct costs, non
adherence is also a risk factor for a variety of subsequent poor health outcomes, including as
many as 125 000 deaths each year (10).
From several studies reported that non-adherence to therapy is the major problems to control TB
in developing countries. The dual infection of Tuberculosis and HIV presents further adherence
problems because of high pill burden and adverse effects. Adherence to treatment is the key to
success. Directly observed therapy is the best choice in ensuring patients compliance on
treatment (11-13).
However, the prevalence of adherence and its associated factors have not been studied in those
HIV postitve patients who are on isoniazid prevent therapy that are found in addis ababa.These
information gap are very crucial to provide a basis for possible interventions on TB/HIV
program in the managment of non-adherence to IPT.Therefore, The objective of this study is to
determine the level of adhrence and to identify those factors that are associated with adherence
to IPT so as to provide information that would be important for furture decisions on TB/HIV
program for the improvement of adherence to IPT.
32 Literature Review
2.1 Global and National TB/HIV Burden
TB is the major public health problem throughout the world.One third of the world population is
estimated to be infected with tubercle bacilli and hence at risk of developing active
disease.Globally in 2008,the annual incidence of TB,expressd as the number of new TB cases
was about 9.4 million people (139 per 100000 population).Among the 15 countries with the
highest estimated TB  incident rates 13 are in Africa.Ethiopia stands 7th place in the global rank
by estimated number of TB cases (14, 15).
TB although curable, is one of the most common causes of HIV-related illness and death. 11.5
million adults living with HIV/AIDS are estimated to be co-infected with Mycobacterium
tuberculosis, with 71% of those co-infected living in sub-Saharan Africa and 22% living in
South-East Asia and 4% in latin america and the caribbean. HIV not only increases the number
of TB cases, but also alters the clinical course of TB disease. The life time risk of developing TB
in HIV negative person is 5-10% where as in HIV positive person is 50%.In Ethiopia routine
data from 44 sites in the year 2005/2006 showed 41% of TB patients are HIV positive.Another
routine data collected in 2006/2007 that co-infection is 31%(2, 6).
2.2 Impacts of TB/HIV
As resource-limited countries rapidly expand their HIV/AIDS treatment and care programs,
TB/HIV co-infection is now a major public health threat for people living with HIV and the
community. Globally, there were 700,000 TB cases among people living with HIV in 2006.
There were an estimated 0.5 million deaths among incident TB cases who were HIV positive in
2008 despite the fact that TB is curable (9, 15). The HIV pandemic presents a massive challenge
4to global TB control. The prevention of HIV and TB, the extension of WHO DOTS programs,
and a focused effort to control HIV-related TB in areas of high HIV prevalence are matters of
great urgency(16).
2.3 Global and National Response Against TB/HIV
In 2004 WHO issued a policy on TB/HIV collaboratives activities to accelerate implementation
of the twelve recommended activites including IPT to reduce the impact of TB/HIV co-infection.
Prevention and treatment of TB in people living with HIV is an urgent priority for both
HIV/AIDS and TB programs. The Three I’s, Isoniazid preventive treatment (IPT), intensified
case finding (ICF) for active TB, and TB Infection Control (IC), are key public health strategies
to decrease the impact of TB on people living with HIV(9, 12).
Collaborative TB/HIV activities are essential to ensure that HIV-positive TB patients are
identified and treated appropriately, and to prevent TB in HIV-positive people. These activities
include establishing mechanisms for collaboration between TB and HIV program; infection
control in healthcare and congregate settings; HIV testing of TB patients and – for those TB
patients infected with HIV – Cotrimoxazole preventive therapy (CPT) and ART; and intensified
TB case-finding among people living with HIV followed by IPT for those without active TB(12).
Ethiopia has begun responding to the TB and HIV epidemic since 2001. In 2004 the national
TB/HIV collaborative activities strategy has been developed and implemented in 2008.
implementation Guidelines for TB/HIV collaborative activities in ethiopia has been developed
and IPT implementaion has been scaled up(1, 14).
52.4 Isoniazid Preventive Therapy
Preventive therapy (PT) against tuberculosis is the use of one or more anti-tuberculosis drugs
given to individuals with latent infection with Mycobacterium tuberculosis in order to prevent
the progression to active disease. HIV is the most powerful known risk factor for progression
from latent infection with M. tuberculosis to active disease, and this is the major cause of the
large increase in the incidence of tuberculosis in populations with a high prevalence of HIV
infection over the last decade. WHO issued policy recommendations for IPT In 1998 (17).
Several studies showed that Isoniazid prevent therapy prevents development of Active TB in
HIV postitive patients.Treatment with Isoniazid of indivuals who are both Tuberculin Skin
Test(TST) and HIV  postive, living in a setting with high prevalence of TB, reduce the risk of
developing active TB by 60%.In stituation where TST is not performed  treatment of HIV
positive individuals with Isoniazid reduce the risk of developing active TB by 40%.If TST is not
available individuals with HIV positive and living in population with a high prevalence of
M.tuberculosis infection esitmated to be >30%, health care workers, houseshold contacts of TB,
prisoners, miners and other selected groups at a high risk of acquiring or transmitting TB should
be considered for preventive therapy(18, 19).
A study to show  on the effectivenes of preventive therapy 12 trials were included with a total
of 8578 randomized participants. TB preventive therapy (any anti-TB drug) versus placebo was
associated with a lower incidence of active TB. This benefit was more pronounced in individuals
with a positive tuberculin skin test than in those who had a negative test (20).
In another studies in which placebo-controlled were carried out in Haiti, Zambia, and Kenya
with varying designs and results. In the Haitian study, a 12-months course of Isoniazid
significantly reduced the incidence of tuberculosis among HIV-positive subjects with positive
6tuberculin skin tests. In the Zambian study, a six-month course of Isoniazid reduced the
incidence of tuberculosis among patients with positive tuberculin skin tests. However, in the
study from Kenya there was no effect of six months of therapy with Isoniazid among HIV-
positive subjects(21). The use of both IPT and ART in HIV-infected patients is associated with
significantly reduced tuberculosis incidence (22).
In another study also (1) daily (INH) for 6 months, (2) daily INH and rifampin (RIF) for 3
months, and (3) twice-weekly RIF and Pyrazinamide (PZA) for 2 months of TB preventive
therapy taken by HIV-infected tuberculin reactors in sub-Saharan Africa results in extended life-
expectancy, reduction of the incidence of TB and monetary savings in medical care and social
costs (23, 24).
Regarding the adherence rate in those HIV postive patients taking INH a study at Dareselam on
Police officers  showed that adherence rate found to to be 65.5%. That was comparable to other
studies in Uganda which was 62% and for Thailand the adherence rate was 67.5%  but it was
much less than the 83.7% rate in the Mexican. In the South Africa study the adherence rate was
found to be 72% which is less than a recent study that was conducted in Cambodia that was
found to be 86%.Acrossectional study that was conducted in Diredawa sub city by TadeseD,
reveald that the adherence rate was 84.86% (25-31).
A study in children overall adherence to Isoniazid was excellent, with a mean adherence of
94.7%. Similar mean adherence was achieved by the group taking daily medication and by the
three times a week group but Children from overcrowded homes were less adherent (32).
A comprehensive review, showed that there are several factors for non compliance of patients to
a recommended medical  treatement.Demographic variables age, sex, marital status, number of
7people in the household, social class) and disease factors are poor indicators of compliance.
Although some associations have been found, the direction of these associations was inconsistent
between studies. Treatment factors, such as the duration of the treatment, the number of
medications prescribed, the cost, and the frequency of dosing generally, the higher the levels of
these factors, the lower the compliance. Factors that have been found to relate to high
compliance include the degree of disability, perhaps due to increased supervision, and parenteral
medication administration.The complexity of the regimen and poor communication are often
mentioned as common causes of non-compliance, especially in elderly patients with memory
disorders, which make them unable to follow complex sets of instructions. Other factors
associated with compliance are patients' beliefs about medications and about medicine in
general. Their own knowledge, ideas and experiences, as well as those of family members and
friends, have been shown to correlate with compliance(10).
Tuberculosis control programs must be tailored to take into account the importance of cultural
factors also in promoting compliance with therapy (33). A study in rural South Africa  Barriers
to adherence included fear of stigmatization, lack of money for food and transport, the belief that
HIV is incurable, competition between Western and traditional medicine, and a reluctance to
take medication in the absence of symptoms. Disclosure of HIV status, social and family
support, and a supportive clinic environment positively influenced adherence in another study
that was conducted Latino immigrant samples.Non-adherence due to adverse reactions was
documented in only three cases (5.7%) Other reasons for non-adherence included refused
services (9.4%) and moved (3.8%) (34, 35).
8Reasons for non-adherence in another study showed that among five patients who had no INH
detected in their urine, claimed to have run out of pills within the previous 72 hours. In another
study where consecutive patients were recruited. 32 (37.2%, 95% CI 25.4, 45.0) of the 86
patients who received INH from peripheral pharmacies said the pharmacy had run out of INH at
some time (29, 36). A study that was conducted in Thailand on Level of adherence and factors
associated with adherence to IPT managed to identify in those individuals who were non-
adherent to IPT, Out-migration for job search in other provinces was the predominant reported
reason for non-adherence. Other significant reasons includes denial of HIV-infection status,
perceived side effects of Isoniazid, and misunderstanding about duration of the preventive
therapy(28). In another study the most common reasons for non adherence mentioned by those
study subjects were bieng away from residential area, stock out at facilities,forgetfulness and
runnig out of pills that acounts 75%(n=52) (30).
Though IPT reduce the incidence of TB  a systematic review of data published since 1951 to
assess the effect of primary IPT on the risk for Isoniazid- resistant TB by using different
definitions of Isoniazid resistance, showed that using Isoniazid monotherapy to treat latent TB
infection could promote Isoniazid-resistant TB (37).
In summary, The literature review shows that adherence to IPT treatment has been studied across
different settings in those HIV positive patients who are taking INH and showed that non
adherence to IPT treatment remains a problem in different parts of the world, although the
magnitudes differ. Many factors seem to influence IPT treatment adherence.However there are
no studies conducted on IPT adherence in those HIV patients who are assumed to be infected
with tuberculosis and taking isonizid in selected public health facilities of Addis Ababa.
9Adherence to Isoniazid
preventive therapy
Figure 1, Conceptual framework  how different factors affect  adherence to IPT
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3 Objectives
3.1 General Objectives
To assess the prevalence of adherence   to Isoniazid  preventive therapy  and associated factors
among PLHIV on Isoniazid preventive therapy.
3.2 Sepecific objectives
1.To determine the prevalence of adherence  to Isoniazid preventive therapy  among  PLHIV.
2.To identify factors associated with adherence to Isoniazid preventive therapy  among PLHIV.
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4. Methodology
4.1. Study setting
4.1.1. Study area and period
The study was conducted at Addis Ababa the largest city in Ethiopia, with a population of 2.74
million. Addis Ababa Health bureau (AARHB) is responsible for both curative and preventive
health care services in the city.There are 10 subcity health departments which are directly
accountable to their respective sub-city adminstrations. Totally there are 38 hospitals in the
metropolis of which 5 are under Addis Ababa Regional Health Bureau , 5 under Federal ministry
of health ,2 under NGO,2 are under the minstry of defence, 1 police hospital and 23 are private
hospitals.There are 27 Health centers of which 24 are owned by the city adminstration,2 by NGO
and 1 by the community.The potential health service coverage in Addis Ababa with regard to
geographical accessibility is 100% (38). The study was conducted from December 2010 to
February 2011.
4.2. Study Design:
Cross-sectional health facility based study design was used by quantitative data collection
method to asses the prevalence of isoniazid preventive therapy adherence and its associated
factors in 12 selected health facilities of Addis Ababa.
4.3 Source population: The source population for this study was all HIV infected clients who
had been enrolled to chronic HIV care and  under IPT  in Addis Ababa.
4.4 Study population: The study populations were  all HIV infected individuals who had been
under  IPT in the period of August 2010-January 2011.
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Inclusion criteria: Those patient who had been on IPT  >=18 years of age for whom informed
consent can be obtained and patients who had taken INH at least for 1 month.
Exclusion crieteria: HIV postive patients who are seriously ill were excluded from the study.
4.5 Variables
4.5.1 Dependent Variable:Adherence to IPT
4.5.2 Independent variables: Socio demographic characteristics (age, sex, marital status,
education, religion, occupation, ethnicity…) , time to health facilities, long waiting time,cost of
transport, ART taking status, ART disclosure status.
4.6 Sample size Determination
Sample size: n0 = Z (α/2)2 * P (1-P)
d2
Sample size  1
Assumptions.
Z (α/2) = Z score at 95% CI =1.96
P= Adherence rate of Isoniazid preventive therapy from a study that was conducted in South
Africa was (72%) (29).
d = margin of error = 4%
n0= Z (α/2)2 * P (1-P)
d2
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n0 = (1.96)2 * 0.72 (1-0.72)= n0= 484
(0.04)2
Since the Number of HIV positive individuals who were on IPT was  <10,000 by using finite
population correction formula that is
n= n0/[1+ n0/N]
n0=484
N=1550
n=484 =  369
[1+484/1550]
Non-response rate=10%=369*10%=36.9~37
n=369+37=406
Sample size  2
For factors  associated with adherence from a study that was conducted in Thailand showed that
Sex has significant association for adherence (28). Using epi-info statcal taking only 95%
confidence interval and 80% power  gives the following out put.
Factors Adherence in
un exposed
Adherencein
exposed
Unexp:Exp Sample size Total sample
size including
10% non
response rate
Unexposed exposed
Sex 68.93%(Male) 31.08% (female) 1:1 31 31 68
4:1 76 19 105
3:1 60 20 88
1:3 20 61 89
1:4 19 76 105
From the above calculation  the maximum sample 406 is greater than the sample size  2
that is 105 hence  the final sample size for the exit interview taken was 406.
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Sample size determination for patient Exit interview, Addis Ababa, 2011.
Name of health
facility
Total#PLHIV
started Ipt
% PLHIV on IPT Sample size
(weighted)
Actual # of data
collected and
Analyzed
Minilik Hospital 350 22.6 92 87
Yekatit 12 Hospital 287 18.5 75 71
Beltishachew H/C 61 3.9 16 15
Woreda 24 H/C 59 3.8 15 14
Arada H/C 74 4.8 19 17
Gullele H/C 113 7.3 30 28
Selam H/C 142 9.2 37 35
Nifassilk No1 H/C 98 6.3 26 24
Entoto No1 H/C 104 6.7 27 26
Cazanches H/C 85 5.5 22 21
Addis ketema H/C 98 6.3 26 24
Woreda 7 H/C 79 5.1 21 19
Total 1550 100 406 381
4.7 Sampling procedure: 10 Health centers and 2 Hospitals selected randomly from a sampling
frame consisted of the list  of all 24 health centers and 5 Hospitals that are found  under the
Addis ababa regional health bureau then the calculated sample size was allocated proportional to
their units size. Based on the inclusion criteria  patients were  consecutively interviewed  who
came for follow up to  the healh institutions up on their exit to home until the required sample
size was obtained.Systematic random sampling was not done to due the observed  difference in
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the  patterns of patient appointements across different  health institutions during the pre-test
period.
4.8 Data collection procedures: Data was collected by using structured questionnaire by
interviewing patients upon their exit to home.First the questionnaire was prepared in English
version and then was translated in to Amharic. The Amharic version was back translated into
English version to check for consistency and ensure the quality of translation.There  were  12
Data collectors and 1 supervisor(the principal investigator)  who were health proffesional that
includes health officers and nurses who have basic TB/HIV,ART training and experience and
working in the health institutions. The data was  collected from the selected health facilities from
Dec 2010-Februrary 2011.
4.9 Data Quality Control:
Training was given For data collectors  for two days on how to collect the data from the patients.
The structured questionnaire were pre tested in 5 % of the sample size of people who came to
health facilities other than the  selected health facilities as a result data collectors were
familiarized with the data collection tool and  some amendment were done  on the questionnaire.
Supervisor (the principal investigator) was responsible for checking data completeness and
consistency and on daily basis.
4.10 Operational definitions:
Adherence: Adherence to treatment regimes means taking tablets in all the prescribed doses at
the correct time, in the correct doses and in the correct way. Adherence is measured as the
percentage of tablets taken as prescribed.
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Measuring adherence: For this study adherence was measured as the percentage of doses taken
over the past seven days, as prescribed.
Adherence rate: Based on previous reports on INH treatment efficacy treatment completion or
adhrence was defined as the in take of at least 80% of prescribed doses (39) based on this the
proportion of individuals who slef  reportedly took at least 80% of the prescribed doses of INH
during the past seven days.
Self-reported adherence: Adherence as reported to interviewer, by the study participant, when
administering the questionnaire.
Non adhernce:For an individual said to be non-adherent  if she/he missed at least 2 doses of
INH in the past seven days.
Complete adherence: An individual is said to be completely adherent to IPT if he/she took all
the prescribed  doses in the past seven days.
4.11 Data Management: Collected data were checked for consistency and completeness and
double entered to EPI info version 3.5.1 and the necessary corrections were made.
4.12 Data Analysis procedures: Using stat transfer cleaned data was transferred from EPI info
into SPSS version 16.0 software for analysis and data was summarized using descriptive
statistics by running frequencies and the association of dependent and independent variables
were evaluated using Bivariate and multivariate logistic regression analysis.
4.13 Ethical consideration: Ethical approval was obtained  from Addis Continental Institute of
Public Health  and University of Gondar and also from AARHB to notify and wrote support
letters  to the health  facilities where the actual and pre test was  counducted.Informed consent
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was obtained from all respondents after explaining   the purpose of the study and they were
guaranteed that confidentiality was going to be maintained throughout the study period.
5 Results
5.1 Socio-demographic characterstic
A total of 381 HIV postitve patients who were on isoniazid preventive therapy were
consecutively intervewed  for the study with a  response rate of 93.84%. The mean age of the
study participant was 35.24(+SD 8.54) Majority of the study participants 265(69.6%) were
females where as male accounted  116(30.4%)only. Nearly half of the respondents 187(49.1%)
were in the age group of 28-37 followed by the age group 38-47 that accounted 92(24.1%).
Regrading ethinic group majority of the respondents were Amahara 227 (59.5%) followed by
Oromo 71(18.6%),Tigre 39(10.2%) and Gurage 34(8.9%). The predominant religion of the study
participants was Orthodox christian 317(83.2%) followed by Protestant 32(8.4%) only 27(7.1%)
were muslim respondents.One hundred fifty two (39.9%) of the respondents  have completed
primary education followed by  secondary education accounted  138(36.2%)the rest 66(17.3%),
25(6.6%)were illiterate and Diploma and above respectively.Self employed is the means of
getting income for 170(44.6%) of the respondents,  there were  114(29.9%) unemployed study
participants the rest 97(25.5%) were employed by others.Most of the study participants
329(86.4%) were living  with <=5 people with them in the same house followed by 6-8
44(11.5%) person living with the respondents. Table 1 Illustrates the socio-demographic
characterstics of the respondents.
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Table  1 Socio-demographic characterstic of study participants on Isoniazid preventive
therapy Addis Ababa, 2011.
Variables(n=381) Categories Number %
Sex Male 116 30.4
Female 265 69.6
Age 18-27 62 16.3
28-37 187 49.1
38-47 92 24.1
>=48 40 10.5
Level of education Illiterate 66 17.3
Primary 152 39.9
Secondary 138 36.2
Diploma, and above 25 6.6
Marital status Married 180 47.2
Single 84 22.0
Divorced 60 15.7
Widowed 48 12.6
Separated 9 2.4
Religion Orthodox 317 83.2
Protestant 32 8.4
Muslim 27 7.1
Catholic 4 1.0
Others 1 0.3
Ethnicity Amhara 227 59.6
Oromo 71 18.6
Tigire 39 10.2
Gurage 34 8.9
Sidama 2 0.5
Others 8 2.1
Family size =<5 329 86.4
6-8 44 11.5
>9 8 2.1
Occupation Self-employed 170 44.6
Employed by others 97 25.5
Unemployed 114 29.9
Monthly income <100 ETB 12 4.5
101-300ETB 71 26.6
301-500 ETB 80 30.0
>500ETB 104 39.0
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5.2 Results of  Prevalence of adherence to Isoniazid preventive therapy
The prevalence of self reported  adherance rate of isoniazid is found to be 89.5% with  95%
CI(86.11-92.29) which was found by the proportion of individuals who self reportedely  took at
least 80% of their pills prescribed by the helath care providers in the past seven days.Those
patients who missed at least two or more  doses of isoniazid pills were considered as non-
adherents and accounted 10.5%  with 95% CI(7.71-13.89). (Table 2).
Table. 2 Prevalence of adherence to Isoniazid preventive therapy, Addis Ababa,
2011.
Name of health
facility
Complete
adherence
Adherence
rate
Minilik Hospital 89.7% 90.8%
Yekatit12 Hospital 84.5% 91.5%
Beltishachew H/C 73.3% 86.7%
Woreda 24 H/C 92.9% 92.9%
Arada H/C 76.5% 88.2%
Gullele H/C 96.4% 100%
Selam H/C 74.3% 85.7%
Nifassilk No1 H/C 66.7% 75%
Entoto No1 H/C 92.3% 96.2%
Cazanches H/C 76.2% 76.2%
Addis ketema H/C 70.8% 87.5%
Woreda 7 H/C 73.7% 94.7%
Total % with in
facility
82.7% 89.5%
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5.4. Factors associated with adherence
A crude analysis was done to assess existence of   any association between the independent
variables and adherence to Isoniazid preventive therapy. In bivariate logistic regression some
variables were found to have significant association with adherence includes patients ART taking
status patient who were  exposed  to ART were found to have positive association with
adherence. Those patients who were taking antiretroviral drug were more likely to be adherents
having crude OR 1.972 (1.014-3.835) than those patients who were on Pre-ART with p<0.05.
Hours passed since last dose was positively associated with adherence. Those respondents who
reported to take their pills in the range of 1-11 hrs before the interview were more likely be
adherents than to those respondents who did not remember when took their last dose having
crude OR 3.793(1.492-9.641). Those respondents who have taken INH for >=5 months were
more likely to be adherents than those who took for 1-2 months having crude OR 3.856(1.24-
11.996).Individuals who were explained about  the reasons for taking Isoniazid preventive
therapy by their doctors/nurses  were found more likely to be  adherents than those who did not
have information why they are taking Isoniazid having crude OR 6.831(1.47-31.704).Variables
that were not significant but marginally significant having p value <0.1 and < 0.2 were
considered in the multivariate logistic regression analysis which has the potential to control
possible confounders. In multivariate logistic regresion two independent variables were found to
have significant association with adherence when the other variables were adjusted.Those
patients who were on isoniazid treatement  for >=5 months were more likely to be adherents
than those who took 1-2 monhts AOR[(95%CI)= 5.091(1.412-18.359)].The second variable was
decision that were made by friends for the patients to start isoniazid preventive therapy were less
likely to be adherent than decision made by the patients them selves AOR
[(95%CI)=0.096(0.011-0.815)] (Table 3).
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Table 3. Factors associated with Isoniazid preventive therapy adherence, Addis Ababa, 2011.
Variables Adherent(n=381) OR(95% CI) P.Value
Yes No Crude Adjusted
Age 18-27 50 12 1.00 1.00
28-37 171 16 2.565(1.139-5.778)* 2.128(0.816-5.550) 0.123
38-47 82 10 1.968(0.792-4.889) 1.246(0.419-3.707) 0.693
>=48 38 2 4.56(0.963-21.597) 3.592(0.635-20.336) 0.148
Sex Male 108 8 1.00 1.00
Female 233 32 0.539(0.241-1.21) 0.432(0.161-1.64) 0.097
Occupation Self-employed 149 24 0.585(0.268-1.275) 0.396(0.152-1.033) 0.058
Employed by
others
88 6 1.458(0.510-4.169) 0.736(0.219-2.47) 0.620
unemployed 104 10 1.00 1.00
Patient ART taking
status
Pre-ART 100 18 1.00 1.00
On ART 241 22 1.972(1.014-3.835)* 1.813(0.819-4.012) 0.142
Last dose taken per
hours
1-11 220 16 3.793(1.492-9.641)* 2.124(0.746-6.046) 0.158
12-23 83 12 1.908(0.709-5.132) 1.385(0.429-4.467) 0.586
>=24 9 4 0.621(0.151-2.553) 0.258(0.048-1.378) 0.113
Don’t remember 29 8 1.00 1.00
Took so far 1-2months 106 15 1.00 1.00
3-4 months 126 21 0.849(0.417-1.729) 0.862(0.385-1.933) 0.719
>=5 months 109 4 3.856(1.24-11.996)* 5.091(1.412-18.359) 0.013*
Those who disclosed INH taking status
Those who did not  disclosed
245 24 1.701(0.866-3.342) 1.378(0.627-3.032) 0.425
96 16 1.00 1.00
Those with information about INH
Those without information about INH
337 37 6.831(1.47-31.704)* 8.502(0.457-158.25) 0.151
4 3 1.00 1.00
Counseled on adherence
Not Counseled on adherence
338 38 5.93(0.96-36.6111) 1.033(0.034-31.421) 0.985
3 2 1.00 1.00
Made decision to
start INH
The patient 102 5 1.00 1.00
Family 6 1 0.294(0.03-2.932) 0.987(0.071-13.675) 0.992
Friends 6 2 0.147(0.023-0.921)* 0.096(0.011-0.815) 0.032*
Doctors/Nurses 227 32 0.348(0.132-0.918) 0.456(0.141-1.474) 0.934
INH may be
dangerous to your
health
Strongly
agree/agree
85 18 1.002(0.383-2.619) 1.052(0.32-3.46) 0.934
Strongly
disagree/agree
223 15 3.154(1.197-8.309)* 3.161(0.947-10.544) 0.061
Don’t know 33 7 1.00 1.00
Chance of getting
sick from TB
without treatment
High 225 23 1.761(0.768-4.035) 1.884(0.702-5.059) 0.209
Average/Below
Average
66 8 1.485(0.535-4.122) 1.121(0.334-3.767) 0.853
Don’t know 50 9 1.00 1.00
*Statistically significant at 5%, 1.00 reference group
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5.5 Reasons for non-adherence
Among the reasons mentioned by patients for being non-adherence the predominant were
forgetting, out of stock of Isoniazid in the facilities, side effects and patients away from home
were among the reasons. Figure 2 illustrates the reasons mentioned for non-adherence.
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6. Discussion
This study has tried to assess the prevalence adherence and associated factors on patients who
were on IPT in selected health facilities of Addis Ababa. This study found adherence rate of
89.5% and the major factors associated with adherence were duration on treatment and decision
for initiation of treatment.
In this study it was found that 89.5% of the study participants had taken at least 80% of   their
prescribed pills in the past seven days making the adherence level of Isoniazid preventive
therapy 89.5%. This was higher than what was reported in Diredawa sub city in public health
facilities and the adherence level was 84.86% and also higher with a recent study that was
conducted in Cambodia the adherence level was 86% (30, 31). This study has shown also  higher
level  of adherence to Ionized preventive therapy  when compared with a study that was
conducted in Uganda and Tanzania with the level of prevalence of 62% and 65.5%
respectively(27).This adherence level  variation may be explained by the fact that the study was
conducted many years back when the integration of TB/HIV services may  not have been
developed as the current situations. In another study that was conducted in South Africa showed
that the adherence rate was 72%(29) which is lower than also from this study though level of
adherence was measured by more objective method that involved is a biochemical test called
the Arkansas method, where a chemical reaction with urinary INH metabolites produces a visible
blue color change and self report method. Those study participants who self reported to have
missed doses were more likely to be found to have a negative INH test in their urine. This study
also almost showed higher level of adherence with the study conducted in Mexico that was
83.7% (25).In which a clinical trial was conducted among HIV-1 and PPD+ subjects in Mexico
City Compliance was measured by attendance to visits has been of 83.7% this adherence level
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difference could  be explained also by the the measurement variation used in the study. The level
of adherence is still higher than a study that was conducted in Thailand which was 67.5%(28)
and this huge variation probably explained by the methodology used it  was a prospective cohort
study design and level of adherence was done by pill count at each visit of patients to the health
facilities. In general the level of non- adherence 10.5% is good when compared with other
studies reported so far having non-adherence level ranges from 14-38% (25-31).
In multivariate analysis the variable patients duration on Isoniazid preventive therapy who took
for >=5 months were more likely to be adherents than who took for 1-2 months. This finding is
paradoxical with a study conducted on latent tuberculosis prevention therapy in Latino
immigrants in which Adherence dropped from 98% in month 2 to 72% at 9 months that means
initially patients were more likely to be adherents than at the end of the treatments. This variation
could be explained by the repeated counseling services that patients would have obtained in the
health facilities during the long follow up period than they obtained initially made the patients to
be more adherents (35). In this study pertaining to decision of initiation of Isoniazid preventive
therapy those decision made by friends to the patients were found to have negative association
with adherence than those decision made by the patient themselves. This could be explained also
due peer/friend influence patients may start taking INH but they may fail to adhere to treatment
showing that they don’t have knowledge or self efficacy by themselves.
In this study among the reason’s mentioned by those study participants failed to adhere in the
past seven days, the predominant reason was forgetting  to take pills this finding is consistent
with other several study conducted on adherence for long term treatments and also for
tuberculosis preventive therapy as a predictor for non-adherence. In a study that was done in
Diredawa among(21.15%) of the study participants  were reported to have missed doses as a
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result of forgetting the same was true in a   study that was conducted in south Africa 14% of the
study participants agreed that they missed doses sometimes and were found to have negative
urine test during the study period. In this study patients were unable to remember taking their
pills accounting 27.78% of the non-adherents mentioned forgetting as a reason. This requires a
program to strengthen the adherence of patient through memory aids. The other reason for non-
adherence mentioned by patients was in availability of drug at the health facility that was raised
by 8 study participants though this study does not assess the availability of INH in the facilities
through observation taking into consideration  of the study participants this has impact on
adherence. This was the case also in south Africa were peripheral pharmacy were run out of
stock of INH at some time as a result 10(55.6%) patients were forced to miss doses due to this.
Regarding side effects this study find out that 12.96% of the respondents had reported to have a
side effect which was 2 times higher than that was reported in the South Africa. In Tanzania 14%
of individuals had side effects as a result they were forced to miss doses and considered as non-
adherents (29, 40).The other reason mentioned were patients were too ill to take INH report by 7
patients. The other reason was patient away from home around 7.41% this is similar to a study
that depicted patients out migrate in search of jobs (28). Among the community factors expected
to affect adherence stigma was mentioned by only 4 patients which was higher 58% in the
Tanzania study(40).
Variables age, sex, income, time to health facilities, waiting time, ART taking status, disclosure
of Isoniazid taking status, disclosure of HIV status were not found to have significant association
with adherence. The limitation of this study includes adherence level was assessed by self report
which is subjected to recall and social desirability bias as a result level of adherence could be
over estimated at the same time  association could be underestimated. The other limitation was
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no standard questionnaires to adapt in the context of the study area as a result some important
predictor variables might have been missed in this study.As to my search there was no study
conducted in Addis Ababa focusing on the level of adhrence to Isoniazid preventive therapy this
could be strength of this study and put the thesis as a base line for further study.
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Conclusion
In this study the adherence level of Isoniazid preventive therapy is higher than when compared
with the findings of other countries and it is in the acceptable level.
Among the associated factors for adherence those patients who took INH for >=5 months were
found to be more likely to be adherents than those who took between 1-2 months. Decisions that
made by friends to start INH for the patients were less likely to be adherent than decisions made
by the patient themselves.
Among the reasons mentioned for being non-adherent forgetting was the predominant one
followed by, stock out of INH at the health facility level and side effects.
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Recommendation
For Researchers
Based on this study the prevalence of adherence to Isoniazid preventive therapy is good but
further study involving objectively assessing adherence and cohort study to detect better the
prevalence and associated factor is recommended.
For TB control and AIDS programmers, health facility level managers and workers
Counseling should focus to those patients who are in first and second months of follow up.
For those non-adherents as a result of forgetting, availing cellular phone alarms as reminders,
memory aids like diary card, watch’s for alarming treatment times for the patients and Patients
should also enlist friends to remind one to take his/her treatment is recommended also.
Currently existing Information Education Communication (IEC) intervention on HIV/AIDS and
IPT should be strengthened at individual and community level in order to reduce peer/friend
influence on the decision of initiation of Isoniazid preventive therapy
Behavior change communication (BCC) should be strengthened to change stigma and
discrimination by some community members to create awareness.
Patient- health provider relationships should be strengthened so that pre arrangements can be
done to address those non-adherents who goes away from their areas for a certain period of time
without their pills.
Should work on also availing INH drug in a regular manner based the available beneficiaries of
INH.
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Annex I Consent Form English Version
Consent form
My name ________________________________________.This study is for partial fulfillment
of a post graduate program  provided by Addis continental institute of public health and
university of Gondar.The reason why we are here is that we came to study about the isoniazid
preventive therapy.i want to talk with you about your isoniazid medication usage.The
information that you give us will help in collecting  data on the proper utilization and adherence
to isoniazid.The result of the study will help also on the planning and implementaion of on the
improvement of isoniazid preventive therapy usage.The questions will take about 10-20 minutes
to be filled and the information that you give us  will be confidential.your involvement on this
study is very important  but your willingnes is also  necessary.so you will not be forced to
answer those question that you don’t want. For futher information you can contact Mr Melaku
Berhe Habta with the Phone no 091111675 at any time who  is the principal investigator of this
study.if you have question about the study? Shall i start asking?
Name of interviewer________________________Participant signature__________________
Date_____________________________________________________________________
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Annex II Consent Form Amharic Version
የ ተሳ ትፎ ስምምነ ት ማረ ጋ ገ ጫ
ስ ሜ ይባ ላ ል ፣ በ አ ዲስ ኮ ን ቲ ነ ን ታል ኢን ስ ቲ ት ዩ ት ኦ ፍ
ፐ ፕ ሊክ ኼል ዝ እ ና በ ጎ ን ደ ር ዩ ኒ ቨ ር ሲቲ በ ጋ ራ ለ ሚሰ ጥ የ ድህ ረ ምረ ቃ ስ ል ጠና ማሙያ የ ሚደ ረ ግ
ጥና ት ነ ው፡ ፡ ስ ለ አ ይሶ ኒ ያ ዛ ይድ መከ ላ ከ ል ህ ክ ምና ለ ማጥና ት መጥተ ና ል ፡ ፡ ስ እ ር ስ ዎ
የ አ ይሶ ኒ ያ ዛ ይድ መድኃ ኒ ት አ ጠቃቀምን በ ተመለ ከ ተ ላ ና ግ ር ዎት እ ፈ ል ጋ ለ ሁ፣ የ ሚሰ ጡን መረ ጃ
የ አ ይሶ ኒ ያ ዛ ይድ መድኃ ኒ ት ን በ አ ግ ባ ቡ ለ መጠቀም የ ሚያ ግ ዙ መረ ጃ ዎች ን ይሰ በ ስ ባ ል ፣ የ ጥና ቱ
ውጤትም አ ጠቃቀሙን ለ ማሻ ሻ ል የ ሚያ ስ ች ሉ ስ ል ቶ ች ን ለ መን ደ ፍ ና ለ መተ ግ በ ር ይረ ዳ ል ፡ ፡
ጥያ ቄ ዎቹ 10-20 ደ ቂ ቃ የ ሚወስ ዱ ና ቸው፡ ፡ የ ሚሰ ጡን መረ ጃ በ ሚስ ጢር የ ተጠበ ቀ ይሆና ል ፡ ፡
በ ዚ ህ ጥና ት ውስ ጥ የ ሚያ ደ ር ጉ ት ተ ሳ ት ፎ እ ጅግ አ ስ ፈ ላ ጊ ቢሆን ም የ እ ር ስ ዎ ሙሉ ፈቃደ ኝ ነ ት
ያ ስ ፈ ል ጋ ል ፡ ስ ለ ዚ ህ መመለ ስ የ ማይፈ ል ጓ ቸውን ጥቄ ዎች እ ን ዲመል ሱ አ ይ ገ ደ ዱም:ለ ተጨማሪ
መረ ጃ አ ቶ መላ ኩ በ ር ሄ የ ዚ ህ ጥና ት ዋ ና መሪ በ ስ ል ክ ቁ ጥር 0911116735 ማግ ኝ ት ይች ላ ሉ ::
ስ ለ ጥና ቱ ጥያ ቄ ካ ለ ዎት ? አ ሁን መጠየ ቅ ል ጀምር ?
የ ጠያ ቂ ውስ ም የ ጥና ቱ ተ ሳ ታፊ ፊ ር ማ
36
ቀ ን _____________________________________________________________________
37
Annex III Questionnaire English Version
Questionnaire
ASSESSMENT OF ISONIAZID PREVENTIVE THERAPY ADHERENCE AND ITS
ASSOCIATED FACTORS IN SELECTED PUBLIC HEALTH FACILITIES OF ADDIS
ABABA.
Information about the interview
Date of the visit..........................................................................
Health facility Name................................................................
Code of the facility.................................................................
Name of interviwer...................................................................
Questionnaire checked and attested to be preperly completed
Name of supervisor.........................................................................................
Signature.............................................................................................................
Date...........................................................................................
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1) Socio-demographic characterstic
S. No Questions Response categories Skip
pattern
101 How old are you?
---------------
102. What is your sex? Male............................................................. 1
Female............................................................2
103. What is your
Ethnicity? Tigre....................................................................1
Amhara................................................................2
Oromo.................................................................3
Gurage.................................................................4
Sidama.................................................................5
Others (please specify)______________
104. What is your religion? 1) Orthodox Christian..........................................1
2) Protestant.........................................................2
3) Catholic.............................................................3
4) Muslim...............................................................4
5) Others ( specify)-----------------
105. What level of
education have you
completed?
Illiterate. .......................................1
Primary..........................................2
Secondary......................................3
Diploma,First Degree and above...4
106 What is your marital
status?
Married..........................................................1
Single.............................................................2
Divorced........................................................3
Separated.......................................................4
Widowed........................................................5
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107. What is your
occupational status ? Self employed.....................................................1
Employed by others ...........................................2
Unemployed.......................................................3
IF 3 skip
to 109
108 What is your monthly
average income ?( In
Birr)
_______________(Birr)
109 Including yourself,
how many people live
in your household?
_____________(Number)
110 How do you get to this
HC/Hospital?
Walk...........................................................1
Bicycle........................................................2
Bus ............................................................3
Car .............................................................4
Taxi.............................................................5
Others(speicify)_____________
IF 1, 4
skip to
112
111 How much birr did you
pay for transportaion?
________________________(Birr and Cent)
112 How much time does it
take you to get to this
HC/Hospital?
___________________________(in minutes)
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2 Patients, Health system and Family Support Information
S. No Questions Response categories Skip
pattern
201 How long did you stay to get the
services in this facility today? -------------(in minutes)
202 What is your Antiretroviral drug
taking staus?
Pre Art.......................................1
Art..............................................2
203 Have you been taking your INH
pills?
Yes .............................................1
No................................................2
204 If yes to Q 203 how often, do
you take them?
Every day……………………………1
5 - 6 days per week………………….2
3 - 4 days per week………………....3
< 3 days per week…………..………....4
205 When did you take the last dose? ___________________(hours ago)
Don’t remember…………………89
206 How long will you be taking this
tablet?
For 6 months............................................1
For 9 months..............................................2
Don’t know.................................................3
Other(specify)__________
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207 For how long did you take so
far?
1 month.....................................................1
2 months.....................................................2
3 months......................................................3
4 months......................................................4
5 months.......................................................5
6 months........................................................6
208 Would you describe why you are
supposed to take the INH pills?
Mentioned       Not mentioned
Fear of Tuberculosis        1                        2
Understanding of the 1                        2
Importance of IPT
Fear of HIV and TB          1                         2
complication
Recommended by the       1                         2
doctors
209 Can you tell me the name
treatement that your are on?
Yes.........................................................1
No..........................................................2
IF No skip
to 211
210 If yes to question  209 What is
the name of the drug?
Isoniazid................................1
ART.......................................2
Other(specify)_________
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211 In a normal day, how many pills
do you have to take?
1 pill.....................................................1
2 plls.....................................................2
Don’t know........................................99
212 Have you told anybody that you
are taking INH?
Yes ....................................1
No......................................2
IF No skip
to 214
213 For whom did you tell that you
are taking INH?
To my husband........................................1
To my wife..............................................2
To my
son.................................................3
To my daughter...................................-...4
To my friends..........................................5
To my relatives......................................6
Others(specify)_____________________
214 Have you told anybody that you
have HIV?
Yes ....................................1
No......................................2
IF No skip
to 216
215 For whom did you tell that you
have HIV?
To my husband........................................1
To my wife..............................................2
To my
son.................................................3
To my daughter.......................................4
To my friends.........................................5
To my relatives......................................6
Others(specify)_____________________
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216 Has your doctor/nurse Explained
to you the reasons for taking the
Isoniazid?
Yes ....................................1
No......................................2
217 Has your doctor/nurse
Counselled you on
treatment adherence?
Yes ....................................1
No......................................2
IF No skip
to 219
218 Did you get the counseling
helpful for your treatment?
Yes ....................................1
No......................................2
219 What do think about  the health
staff attitude about your  IPT
treatment in this facility?
Very rude..............................................1
Respectiful............................................2
Encouraging..........................................3
Morrally suppotive................................4
Others(specify)__________________
220 Do you know any person or
family who had the disease
Tuberculosis?
Yes ....................................1
No......................................2
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221 Does your family member
support you taking this
medication?
Yes ....................................1
No......................................2
N/A.....................................3
222 Has someone to remind you to
take medicine?
Yes ....................................1
No......................................2
IF No skip
to 224
223 If yes t o Q 222 how often did
she/he reminds you?
All the time................................................................1
Sometimes.................................................................2
224 How dificult do you find it
remebering your pills?
Extremely difficult .................................................1
Very difficult ..........................................................2
Don’t really know ..................................................3
Not very difficult ....................................................4
Not difficult at all.....................................................5
225 Who made the decision to start
IPT for you?
The patient himself.......................................1
Family ...............................................................2
Friends...............................................................3
Health
Professionals..............................................................4
Other (specify)_______________
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226 Statement- The INH may be
dangerous to your health
Strongly agree....................................................1
Agree ................................................................2
Disagree .............................................................3
Strongly disagree ...............................................4
don’t know..........................................................99
227 Statement- Without medication,
your chance of getting sick from
TB is:
High ................................................................1
Above average................................................2
Average............................................................3
Below average .................................................4
Don’t know......................................................99
228 Where did you get your
medication most of the time?
From ART pharmacy..........................................1
General pharmacy...............................................2
TB clinic..............................................................3
Others (specify)___________________________
229 Have you missed INH drug in
the past 3 days?
Yes ....................................1
No......................................2
230 If Yes to Q 229 How many
doses did you miss?
____________________________number
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231 Have you missed INH drug in
the past  7 days?
Yes ....................................1
No......................................2
232 If Yes to Q 231  How many
doses did you miss?
____________________________number
233 Have you missed INH drug in
the past  14 days?
Yes ....................................1
No......................................2
234 If Yes to Q 233  How many
doses did you miss?
____________________________number
235 What was the reasons that you
have missed doses?
Mentioned              Not mentioned
Side effects                                   1                          2
Forgotten to take                         1                           2
Too ill                                           1                         2
Stigma/discrimination                  1                          2
Out of stock from health facilities 1                        2
Patient run out of pills              1                             2
Alcohol                                    1                              2
Depression 1                             2
Started other treatment              1                            2
Fasting                                       1                            2
Away from home                       1                           2
Too many pills                           1                           2
Long waiting time                     1                            2
47
Missed appointment                 1 2
High cost of transport               1                            2
Other(specify)_______________________________
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Annex IV Questionnaire Amharic version
መሠረ ታዊ መረ ጃ እ ና የ ቤተሠብ ሁኔ ታ
ቁጥር ጥያ ቄ
መል ስ
101 ዕ ደ ሜዎ ሰ ን ት
ነ ው? እ ድሜበ ሙሉ አ መት [ ]
102. ጾ ታ? ወን ድ .............................................................................1
ሴት ..............................................................................2
103. ብሔር ዎት ምን ድን
ነ ው? ት ግ ሬ ........................................................................1
አ ማራ ....................................................................... 2
ኦ ሮሞ........................................................................3
ጉ ራጌ ........................................................................4
ሲዳ ማ........................................................................5
ሌላ  (ይ ገ ለ ጽ )_______________________________
104. ሀ ይማኖትዎ ምን ድን
ነ ው?
ኦ ር ቶ ዶክ ስ .................................................................1
ፕ ሮቴ ስ ታን ት ..............................................................2
ካ ቶሊክ .......................................................................3
ሙስ ሊም.....................................................................4
ሌላ (ይገ ለ ጽ )_________________________________
105.
ያ ጠና ቀ ቁ ት
የ ትምህ ር ት ደ ረ ጃ
ስ ን ት ነ ው?
ያ ል ተማረ ...............................................................1
የ መጀመሪ ያ ደ ረ ጃ ....................................................2
ሁለ ት ኛ ደ ረ ጃ ...........................................................3
ዲፕሎማ,የ መጀመሪ ያ ድግ ሪ እ ና ከ ዚ ያ በ ላ ይ .........................4
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106 የ ጋ ብቻዎ ሁኔ ታ
ምን ድን ነ ው?
ያ ገ ባ ......................................................................................1
ያ ላ ገ ባ ...................................................................................2
የ ተ ፋ ቱ ...................................................................................3
ለ ጊ ዜውየ ተ ለ ያ ዩ ...................................................................4
ባ ል የ ሞተ ባ ቸው.............................................................................5
107. የ ስ ራዎት ሁኔ ታ
ምን ድን ነ ው ?
1) በ ግ ል የ ሚሰ ራ ......................................................................1
2) በ ሌላ የ ተ ቀ ጠሩ ....................................................................2
3) ያ ል ተ ቀ ጠሩ ............................................................................3
መል ሱ3,
ከ ሆነ ወደ
ጥ ይለ ፉ109
108 ወር ሃ ዊ አ ማካ ይ
ገ ቢዎ ስ ን ት
ነ ው በ ብር?( )
_______________(ብር )
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እ ራስ ዎት ን ጨምሮ
ምን ያ ህ ል ሰ ው
እ ቤትዎት ይኖራል ?
_____________(ሰ ው)
110
በ ምን ድን ነ ው
ወደ ዚ ህ ጤና
ጣቢያ ሆስ ፒ ታል/
የ መጡት ?
በ እ ግ ር ......................................................................1
በ ሳ ይክ ል ..................................................................2
በ ኣ ውቶቢስ ............................................................3.
በ ቤት መኪና ...............................................................4
በ ታክ ሲ .......................................................................5
ሌላ  (ይ ገ ለ ጽ )________________________
መል ሱ1,4,
ከ ሆነ ወደ
ጥ112
ይለ ፉ
111 ምን ያ ህ ል ብር
ለ ትራን ስ ፖር ት
ከ ፈ ሉ
______________________________(ብር ,ሳ ን ቲም)
112 ወደ ዚ ህ ጤና
ጣቢያ /ሆስ ፒ ታል
ለ መምጣት ምን
ያ ህ ል ጊ ዜ
ፈ ጀ ብዎት ?
________________(በ ደ ቂ ቃ )
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ክ ፍል ሁለ ት የ ታማሚው,የ ጤና አ ገ ል ግሎት ,የ ማህ በ ረ ሰብ መረ ጃ
ቁጥር ጥያ ቄ መል ስ
201 አ ገ ል ግ ሎት
ለ ማግ ኘ ት ምን ያ ህ ል
ጊ ዜ ጠበ ቁ በ ዚ ህ ጤና
ድር ጅት ?
-------------(በ ደ ቂ ቃ )
202 የ ጸ ረ ኤች አ ቪ
መውሰ ድ ሁኔ ታዎ ምን
ይመስ ላ ል ?
ቅ ድመጸ ረ ኤች አ ቪ ....................................................1
ጸ ረ ኤች አ ቪ ተጠቃሚ.................................................2
203 አ ይሶ ኒ አ ይዛ ይድ
መድሀ ኒ ት በ መውሰ ድ
ላ ይ ነ ውያ ሉት ?
አ ዎ ................................................................................1
አ ይደ ለ ም......................................................................2
204 በ ምን ያ ህ ል ጊ ዜ
ይወስ ዳ ሉ ?
በ የ ቀ ኑ ........................................................................1
5 - 6 ቀ ን በ የ ሳ ምን ቱ ...................................................2
3 - 4 ቀ ን በ የ ሳ ምን ቱ ....................................................3
< 3 ቀ ን በ የ ሳ ምን ቱ .....................................................4
205 መቼ ነ ውየ ወሰ ዱት
የ መጨረ ሧውን
መድሀ ኒ ት የ ወሰ ዱት ?
_______________________________(ሰ አ ት በ ፊ ት )
አ ያ ስ ታውሱም................................................89
206
ለ ምን ያ ህ ል ጊ ዜ
ይወስ ዳ ሉ ይህ ን
መድሀ ኒ ት ?
ለ 6 ወር ..........................................................................1
ለ 9 ወር ..........................................................................2
አ ያ ውቁ ም..........................................................................99
ሌላ (ይ ገ ለ ጽ )________________________
207 ለ ምን ያ ህ ል ጊ ዜ
እ ስ ክ አ ሁን
ወስ ደ ዋ ል ?
ለ 1 ወር ...........................................................................................1
ለ 2ወር .............................................................................................2
ለ 3 ወር .............................................................................................3
ለ 4ወር ..............................................................................................4
ለ 5 ወር .............................................................................................5
ለ 6ወር ..............................................................................................6
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208 ለ ምን
አ ይሶ ኒ አ ይዛ ይድ
መድሀ ኒ ት
እ ን ደ ሚወስ ዱ
ሊያ ብራሩ ል ኝ
ይች ላ ሉ ?
ተጠ=ተጠቅ ሷል አ ል =አ ል ተ ጠቀ ሰ ም
ተጠ አ ል
ቲ ቢን በ መፍራት 1                        2
የ አ ይሶ ኒ አ ይዛ ይድ የ መከ ላ ከ ል
ህ ክ ምና ን ጥቅም ስ ለ ተ ረ ዱ 1 2
የ ቲ ቢን ና ኤች አ ቪን ጉ ዳ ት በ መፍራት 1 2
በ ሀ ኪም ስ ለ ታዘ ዘ 1 2
209 እ የ ወሰ ዱ ያ ሉት ን
መድሀ ኒ ት ስ ም
ሊነ ግ ሩ ኝ ይች ላ ሉ ?
አ ዎ .........................................................................................1
የ ለ ም......................................................................................2
መል ሱ  2
ከ ሆነ ወደ
ጥ211
210 መል ሱ አ ዎ ከ ሆነ ለ
ጥያ ቄ 209ስ ሙምን
ይባ ላ ል ?
የ አ ይሶ ኒ አ ይዛ ይድ ........................................................1
የ ጸ ረ ኤች አ ቪ መድሀ ኒ ት ...............................................2
ሌላ (ይ ገ ለ ፅ )....................................................................
211 በ አ ዘ ቦ ት ቀ ን ምን
ያ ህ ል መድኃ ኒ ት
መውሰ ድ አ ለ ብህ ?
1 መድሃ ኒ ት ------------------------------- 1
2 መድሀ ኒ ት -------------------------------- 2
3 አ ያ ውቁ ትም ____________________99
212 አ ይሶ ኒ ያ ዛ ይድ
መድኃ ኒ ት
እ ን ደ ሚወስ ዱ
ለ ሌላ ሰ ው ነ ገ ር ዋሉ
?
አ ዎ ----------------------------------------------------------------------------- 1
የ ለ ም ----------------------------------------------------------------------------2
መል ሱ 2
ከ ሆነ 214
ይለ ፍ
213 መል ስ አ ዎ ከ ሆነ
ለ ጥያ ቄ 212 ለ ማ
ነ ገ ር ዋ ሉ
አ ይሰ ኒ ያ ዘ ይድ
እ ን ደ ሚወስ ዱ?
ተጠ= ተ ገ ል ፆ አ ል አ ል = አ ል ተ ገ ለ ፀ ም
ተጠ አ ል
ለ ባ ሌ 1                   2
ለ ሚስ ቴ 1                   2
ለ ወን ድ ል ጄ 1                   2
ለ ሴት ል ጄ 1                   2
ለ ጓ ደ ኞ ቼ 1                   2
ለ ዘ መድ 1                   2
ሌላ ( ይ ገ ለ ፅ )________________________________
214 ኤች አ ይ ቪ
እ ን ዳ ለ ብዎ
ለ ሰ ው ነ ግ ረ ው
ያ ውቃሉ ?
አ ዎ ---------------------------------------------------------1
የ ለ ም--------------------- ---------------------------------2
መል ሱ 2
ከ ሆነ
ወደ ጥ
216ይለ ፍ
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215 ለ ጥያ ቄ 214 መል ስ ዎ
አ ዎ ከ ሆነ ለ ማ ነ ው
የ ነ ገ ሩ ት ?
ተጠ= ተ ገ ል ፆ አ ል አ ል = አ ል ተ ገ ለ ፀ ም
ተጠ አ ል
ለ ባ ሌ 1                   2
ለ ሚስ ቴ 1                   2
ለ ወን ድ ል ጄ 1                   2
ለ ሴት ል ጄ 1                   2
ለ ጓ ደ ኞ ቼ 1                   2
ለ ዘ መድ 1                   2
ሌላ ( ይ ገ ለ ፅ )________________________________
216 የ እ ር ስ ዎ
ዶክ ተ ር /ነ ር ስ ለ ምን
አ ይሶ ኒ ያ ዛ ይድ
እ ን ደ ሚወስ ዱ
ግ ል ፀ ውሎታል ?
አ ዎ ---------------------------------------------------------1
የ ለ ም--------------------- ---------------------------------2
217 የ እ ር ስ ዎ
ዶክ ተ ር /ነ ር ስ
መድሀ ኒ ት በ ት ክ ክ ል
እ ን ዲወስ ዱ ምክ ር
ሰ ጥቶዎታል ?
አ ዎ ---------------------------------------------------------1
የ ለ ም--------------------- ---------------------------------2
218 መል ስ ዎ አ ዎ ከ ሆነ
ለ ጥያ ቄ 217 ሞክ ሩ
ጠቃሚሆኖ
አ ግ ኝ ተውታል ?
አ ዎ ---------------------------------------------------------1
የ ለ ም--------------------- ---------------------------------2
219 የ ጤና ባ ሙያ ዎች ስ ለ
እ ር ሶ
የ አ ይሶ ኒ ያ ዛ ይድ
መከ ላ ከ ል ህ ክ ምና
ያ ላ ቸውአ መለ ካ ከ ት
ምን ይመስ ል ዎታል ?
በ ጣምጨካ ኞች ና ቸው-------------------------------------1
ያ ከ ብራሉ --------------------------------------------------2
ያ በ ረ ታታሉ ------------------------------------------------3
ሞራል ይገ ነ ባ ል ------------------------------------------4
ሌላ (ይ ገ ለ ፅ )______________________
220 በ ቲ ቢ የ ታመመ
ቤተ ሰ ብ ወይም
ማን ኛ ውምሰ ው
ያ ውቃሉ ?
አ ዎ ---------------------------------------------------------1
የ ለ ም--------------------- ---------------------------------2
221
ቤተ ስ ብዎ ይህ ን
መድኃ ኒ ት
በ መውሰ ድዎ
ይደ ግ ፍ ዎታል ?
አ ዎ ---------------------------------------------------------1
የ ለ ም--------------------- ---------------------------------2
222 መድኃ ኒ ት
እ ን ዲወስ ዱ
የ ሚያ ስ ታውሶ ት ሰ ው
አ ለ ?
አ ዎ ---------------------------------------------------------1
የ ለ ም--------------------- ---------------------------------2
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223 መል ስ ዎ አ ዎ ከ ሆነ
ለ ጥያ ቄ 222 በ ምን
ህ ል ጊ ዜ ነ ው
የ ሚያ ስ ታውስ ዎት ?
ሁል ጊ ዜ --------------------------------------------------1
አ ል ፎ አ ል ፎ ----------------------------------------------2
224 መድሃ ኒ ት መውሰ ድ
ማስ ታወስ ምን ያ ህ ል
ች ግ ሆኖ ያ ገ ኙታል
እ ጅግ በ ጣምይከ ብዳ ል ---------------------------------1
በ ጣምይከ ብዳ ል -----------------------------------------2
ብዙም አ ይቸ ግ ረ ኝ ም------------------------------------3
ምን ም አ ይቸ ግ ረ ኝ ም------------------------------------4
አ ያ ውቁ ም_________________________________99
225 ማን ነ ውለ እ ር ስ ዎ
መድሃ ኒ ት
የ አ ይሶ ኒ ያ ዛ ይድ
መከ ላ ከ ል ህ ክ ምና
መጀመር
የ ወሰ ን ሎዎት ?
በ ሽ ተ ኛ ውራሱ --------------------------1
ቤተ ሰ ብ ----------------------------------2
ጓ ደ ኛ ---------------------- --------------3
የ ጤና ባ ለ ሙያ -------------------------- 4
ሌላ (ይ ገ ለ ፅ ) ______________________
226 አ ይሶ ኒ ያ ዛ ይድ
ለ ጤና ዎ አ ደ ገ ኛ
ሊሆን ይች ላ ል ?
በ ጣምይስ ማማሉ ----------------------------------1
ይስ ማማሉ ----------------------------------------- 2
አ ይስ ማሙም --------------------------------------- 3
በ ጣም አ ይስ ማሙም -------------------------------- 4
አ ያ ውቁ ም __________ _________________99
227 ያ ለ መድሃ ኒ ት
የ እ ር ስ ዎ በ ቲቪ
የ መታመምዕ ድል
ከ ፍ ተ ኛ ነ ው------------------------------------- 1
አ ማካ ይ በ ላ ይ ------------------------------2
አ ማካ ይ -------------------------------------- 3
ከ አ ማካ ይ በ ታች --------------------------------- 4
አ ያ ውቁ ም __________________________ 99
228 አ ብዛ ኛ ውን ጊ ዜ
መድሃ ኒ ት ሚያ ገ ኙት
ከ የ ት ነ ው?
ከ ፀ ረ ኤች አ ይቪ ፋ ር ማሲ ----------------------------1
ከ አ ጠቃላ ይ ፋ ር ማሲ ------------------------------- 2
ከ ቲቪ ክ ሊኒ ክ ----------------------------------- 3
ሌላ (ይ ገ ለ ፅ ) ________
229 በ ባ ለ ፈው 3 ቀ ን
ውስ ጥ
አ ይሶ ኒ ያ ዛ ይድ
ያ ል ወሰ ዱበ ት ቀ ን
አ ለ ?
አ ዎ ----------------------------------------------------- ---1
የ ለ ም--------------------- ---------------------------------2
230 መል ስ ዎ አ ዎ ከ ሆን
ለ ጥያ ቁ 229 ምን
ያ ህ ል መድኃ ኒ ት ነ ው
ያ ል ወሰ ዱት ?
-------------------------------( ቁ ጥር )
231 በ ባ ለ ፈው 7 ቀ ን
ውስ ጥ
አ ይሶ ኒ ያ ዛ ይድ
ያ ል ወሰ ዱበ ት ቀ ን
አ ለ ?
አ ዎ ------------------------------------------------------ ----1
የ ለ ም--------------------- ---------------------------------2
232 መል ስ ዎ አ ዎ ከ ሆን
ለ ጥያ ቁ 231 ምን
---------( ቁ ጥር )
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ያ ህ ል መድኃ ኒ ት ነ ው
ያ ል ወሰ ዱት ?
233 በ ባ ለ ፈው 14 ቀ ን
ውስ ጥ
አ ይሶ ኒ ያ ዛ ይድ
ያ ል ወሰ ዱበ ት ቀ ን
አ ለ ?
አ ዎ ----------------------------------------------------- ---1
የ ለ ም--------------------- ---------------------------------2
234 መል ስ ዎ አ ዎ ከ ሆን
ለ ጥያ ቁ 233 ምን
ያ ህ ል መድኃ ኒ ት ነ ው
ያ ል ወሰ ዱት ?
---------( ቁ ጥር )
235 ምክ ን ያ ቱ ምን ድን
ነ በ ር ሳ ይወስ ዱ
የ ቀ ሩ በ ት ?
ተጠ= ተ ገ ል ፆ አ ል አ ል = አ ል ተ ገ ለ ፀ ም
ተጠ አ ል
የ መድሀ ኒ ት የ ጎ ን ዮ ሽ ጉ ዳ ት 1 2
መውሰ ድ እ ረ ስ ተው 1                                  2
በ ጣምታመው 1                                  2
አ ድሎ/መገ ለ ል 1                                   2
መድሃ ኒ ት በ ጤና ድር ጅት አ ለ መኖ ር 1                                    2
መጠጥ 1                                   2
ድብር ት 1                                    2
ሌላ መድሀ ኒ ት መጀመር 1                                     2
ፆ ም 1 2
ከ ቤት መራቅ 1                                    2
በ ጤና ተ ቋ ሞብዙ ጊ ዜ በ መጠበ ቅ 1                                    2
ቀ ጠሮ አ ል ፎ 1 2
ሌላ ( ይ ገ ለ ፅ ) _________
ተጠያ ቂዋን አ መሰ ግን
ተፈጸ መ
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